An Open Label, Non-Randomized Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain 5-HT1A Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK163090, Using the Ligand [11C]-WAY100635.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2012
At a glance
- Drugs GSK 163090 (Primary)
- Indications Anxiety disorders; Depressive disorders
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 18 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Mar 2007 New trial record.